Outline of Use-Results Survey for ORENCIA Subcutaneous Injection 125mg Syringe 1mL
Phase of Trial: Phase IV
Latest Information Update: 18 Jan 2017
At a glance
- Drugs Abatacept (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 12 Jan 2017 Status changed from active, no longer recruiting to completed.
- 19 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.
- 19 Aug 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Sep 2016.